Regulatory Obligation to Reassess Benefit–Risk Balance After Competitor Product Approval

Introduction

The benefit–risk balance is the relationship between a medicinal product’s expected therapeutic benefits and its potential risks, including adverse effects, manufacturing defects, and uncertainty about long-term safety. Regulatory authorities assess this balance when granting marketing authorisation and may reassess it after approval as new evidence becomes available.

A competitor’s approval can be relevant when it introduces new clinical evidence, a different safety profile, or a more effective treatment option. However, approval of a competitor product does not, by itself, create an automatic legal duty to reassess or withdraw an already approved product. The obligation generally arises when the new information is material to the existing product’s safety, efficacy, or regulatory conditions.

Legal and Regulatory Framework

Under the European Union’s medicinal-product framework, marketing authorisation may be varied, suspended, or withdrawn where a product is harmful, lacks therapeutic efficacy, or has an unfavourable benefit–risk balance. These grounds are distinct and must be evaluated according to the evidence.

The European Medicines Agency (EMA) and national regulators continuously monitor safety information, including adverse-event reports, new studies, scientific publications, and periodic safety update reports (PSURs). The marketing-authorisation holder must maintain a pharmacovigilance system and evaluate whether new information changes the product’s risk profile.

European Medicines Agency (EMA)+1

A competitor’s approval may trigger closer scrutiny if it reveals:

A previously unknown safety risk or superior efficacy.

A new treatment standard affecting the existing product’s clinical value.

A relevant difference in contraindications, dosage, or patient populations.

New comparative data that materially changes the product’s benefit–risk assessment.

The competitor’s authorisation alone, without relevant new evidence, is generally insufficient to require suspension or withdrawal.

Important Case Laws

1. Artegodan GmbH v Commission, Case T-74/00 (2002)

The EU General Court held that regulatory authorities may revise a medicine’s benefit–risk assessment in light of new scientific information. It recognised that serious doubts about safety or efficacy may justify suspension or withdrawal under the precautionary principle. The Court also emphasised that reassessment should ordinarily be based on new, objective scientific or medical information. This is a key authority for continuing regulatory review after approval.

Bailii

2. Commission v Laboratoires Servier, Case C-680/16 P (2019)

This case concerned the EU regulatory assessment of medicines and the interpretation of scientific evidence in regulatory decision-making. It is relevant to the principle that regulatory decisions must be based on a proper assessment of the evidence and applicable legal standards. It does not, however, establish an automatic reassessment duty triggered by a competitor’s approval.

3. Ferring Arzneimittel GmbH v Orifarm GmbH, Case C-488/20 (2022)

The Court of Justice discussed pharmacovigilance obligations, including the marketing-authorisation holder’s responsibility to monitor new or changed risks and assess whether the benefit–risk balance has altered. It supports the principle that ongoing safety assessment is a continuing obligation, not a one-time approval requirement.

EUR-Lex

Conclusion

The regulatory obligation to reassess benefit–risk balance is evidence-based and continuing. Competitor approval may provide relevant new information, but it is not an independent legal ground for automatic reassessment, suspension, or withdrawal.

The governing principle is continuous pharmacovigilance and proportionate regulatory action when new evidence materially affects the benefit–risk balance.